References
- Balakrishnan, P., Solomon, S., Mohanakrishnan, J., Cecelia, A. J., Kumarasamy, N., Murugavel, K. G., … Mayer, K. H. (2006). A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. Journal of Acquired Immune Deficiency Syndromes, 43(1), 23–26.
- Cecelia, A. J., Christybai, P., Anand, S., Jayakumar, K., Gurunathan, T., Vidya, P., … Kumarasamy, N. (2006). Usefulness of an observational database to assess antiretroviral treatment trends in India. National Medical Journal of India, 19(1), 14–17.
- Celentano, D. D., Galai, N., Sethi, A. K., Shah, N. G., Strathdee, S. A., Vlahov, D., & Gallant, J. E. (2001). Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS, 15(13), 1707–1715.
- Cox, C., Chu, H., Schneider, M. F., & Munoz, A. (2007). Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Statistics in Medicine, 26(23), 4352–4374.
- Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009). Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet, 373(9657), 48–57.
- Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., … Fischl, M. A. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. The New England Journal of Medicine, 337(11), 725–733.
- Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., … Moore, R. D. (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. The New England Journal of Medicine, 360(18), 1815–1826.
- Kumarasamy, N., Solomon, S., Chaguturu, S. K., Cecelia, A. J., Vallabhaneni, S., Flanigan, T. P., & Mayer, K. H. (2005). The changing natural history of HIV disease: Before and after the introduction of generic antiretroviral therapy in southern India. Clinical Infectious Diseases, 41(10), 1525–1528.
- Mehta, S. H., Kirk, G. D., Astemborski, J., Galai, N., & Celentano, D. D. (2010). Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996–2008. Clinical Infectious Diseases, 50(12), 1664–1671.
- Moore, R. D., Stanton, D., Gopalan, R., & Chaisson, R. E. (1994). Racial differences in the use of drug therapy for HIV disease in an urban community. The New England Journal of Medicine, 330(11), 763–768.
- Sangeetha, P., Sripriya, P., Ganesh, A. K., Duraisamy, P., & Solomon, S. (2006). Enhancing HAART through graduated cost recovery in GFATM – round II objective III [Abstract no. MOPE0706]. Paper presented at the XVI International AIDS Conference, Toronto.
- Solomon, S., Solomon, S. S., & Ganesh, A. K. (2006). AIDS in India. Postgraduate Medical Journal, 82(971), 545–547.
- Sterne, J. A., May, M., Costagliola, D., de Wolf, F., Phillips, A. N., Harris, R., … Cole, S. R. (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet, 373(9672), 1352–1363.
- UNAIDS. (2008). 2008 report on the global AIDS epidemic. Retrieved from http://data.unaids.org/pub/GlobalReport/2008/JC1510_2008GlobalReport_en.zip